Selected research
Industry Research
Human Rabies Immune Globulin (HRIG) Industry Research Report 2026
Market perspective
The global Human Rabies Immune Globulin (HRIG) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Rabies Immune Globulin (HRIG) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Rabies Immune Globulin (HRIG) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Rabies Immune Globulin (HRIG) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Rabies Immune Globulin (HRIG) include Bharat Serum, CBPO, CNBG, CSL Behring, Grifols, Kamada, VINS, Shuanglin Bio and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Rabies Immune Globulin (HRIG) market in terms of revenue (US$ million) and, where applicable, sales volume (K Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Rabies Immune Globulin (HRIG) Market by Company
Bharat Serum
CBPO
CNBG
CSL Behring
Grifols
Kamada
VINS
Shuanglin Bio
Sanofi
Shanghai RAAS
Weiguang Bio
Sichuan Yuanda Shuyang
Human Rabies Immune Globulin (HRIG) Segment by Type
200IU
500IU
Human Rabies Immune Globulin (HRIG) Segment by Application
Category II Exposure
Category III Exposure
Human Rabies Immune Globulin (HRIG) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Rabies Immune Globulin (HRIG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Rabies Immune Globulin (HRIG) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Rabies Immune Globulin (HRIG).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Rabies Immune Globulin (HRIG) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Rabies Immune Globulin (HRIG) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Rabies Immune Globulin (HRIG) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 200IU
- 500IU
Applications
- Category II Exposure
- Category III Exposure
Companies covered
- Bharat Serum
- CBPO
- CNBG
- CSL Behring
- Grifols
- Kamada
- VINS
- Shuanglin Bio
- Sanofi
- Shanghai RAAS
- Weiguang Bio
- Sichuan Yuanda Shuyang
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Rabies Immune Globulin (HRIG) Market Size (2021-2032)
- 2.2.2 Global Human Rabies Immune Globulin (HRIG) Sales (2021-2032)
- 2.2.3 Global Human Rabies Immune Globulin (HRIG) Market Average Price (2021-2032)
- 2.3 Human Rabies Immune Globulin (HRIG) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 200IU
- 2.3.3 500IU
- 2.4 Human Rabies Immune Globulin (HRIG) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Category II Exposure
- 2.4.3 Category III Exposure
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Rabies Immune Globulin (HRIG) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Rabies Immune Globulin (HRIG) Sales (K Tons) of Manufacturers (2021-2026)
- 3.3 Global Human Rabies Immune Globulin (HRIG) Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Rabies Immune Globulin (HRIG) Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Rabies Immune Globulin (HRIG) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Rabies Immune Globulin (HRIG), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Rabies Immune Globulin (HRIG), Product Type & Application
- 3.8 Global Manufacturers of Human Rabies Immune Globulin (HRIG), Established Date
- 3.9 Global Human Rabies Immune Globulin (HRIG) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bharat Serum
- 4.1.1 Bharat Serum Company Information
- 4.1.2 Bharat Serum Business Overview
- 4.1.3 Bharat Serum Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bharat Serum Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.1.5 Bharat Serum Recent Developments
- 4.2 CBPO
- 4.2.1 CBPO Company Information
- 4.2.2 CBPO Business Overview
- 4.2.3 CBPO Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CBPO Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.2.5 CBPO Recent Developments
- 4.3 CNBG
- 4.3.1 CNBG Company Information
- 4.3.2 CNBG Business Overview
- 4.3.3 CNBG Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CNBG Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.3.5 CNBG Recent Developments
- 4.4 CSL Behring
- 4.4.1 CSL Behring Company Information
- 4.4.2 CSL Behring Business Overview
- 4.4.3 CSL Behring Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CSL Behring Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.4.5 CSL Behring Recent Developments
- 4.5 Grifols
- 4.5.1 Grifols Company Information
- 4.5.2 Grifols Business Overview
- 4.5.3 Grifols Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Grifols Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.5.5 Grifols Recent Developments
- 4.6 Kamada
- 4.6.1 Kamada Company Information
- 4.6.2 Kamada Business Overview
- 4.6.3 Kamada Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Kamada Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.6.5 Kamada Recent Developments
- 4.7 VINS
- 4.7.1 VINS Company Information
- 4.7.2 VINS Business Overview
- 4.7.3 VINS Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 VINS Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.7.5 VINS Recent Developments
- 4.8 Shuanglin Bio
- 4.8.1 Shuanglin Bio Company Information
- 4.8.2 Shuanglin Bio Business Overview
- 4.8.3 Shuanglin Bio Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shuanglin Bio Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.8.5 Shuanglin Bio Recent Developments
- 4.9 Sanofi
- 4.9.1 Sanofi Company Information
- 4.9.2 Sanofi Business Overview
- 4.9.3 Sanofi Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sanofi Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.9.5 Sanofi Recent Developments
- 4.10 Shanghai RAAS
- 4.10.1 Shanghai RAAS Company Information
- 4.10.2 Shanghai RAAS Business Overview
- 4.10.3 Shanghai RAAS Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Shanghai RAAS Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.10.5 Shanghai RAAS Recent Developments
- 4.11 Weiguang Bio
- 4.11.1 Weiguang Bio Company Information
- 4.11.2 Weiguang Bio Business Overview
- 4.11.3 Weiguang Bio Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Weiguang Bio Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.11.5 Weiguang Bio Recent Developments
- 4.12 Sichuan Yuanda Shuyang
- 4.12.1 Sichuan Yuanda Shuyang Company Information
- 4.12.2 Sichuan Yuanda Shuyang Business Overview
- 4.12.3 Sichuan Yuanda Shuyang Human Rabies Immune Globulin (HRIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sichuan Yuanda Shuyang Human Rabies Immune Globulin (HRIG) Product Portfolio
- 4.12.5 Sichuan Yuanda Shuyang Recent Developments
5 Global Human Rabies Immune Globulin (HRIG) Market Scenario by Region
- 5.1 Global Human Rabies Immune Globulin (HRIG) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Rabies Immune Globulin (HRIG) Sales by Region: 2021-2032
- 5.2.1 Global Human Rabies Immune Globulin (HRIG) Sales by Region: 2021-2026
- 5.2.2 Global Human Rabies Immune Globulin (HRIG) Sales by Region: 2027-2032
- 5.3 Global Human Rabies Immune Globulin (HRIG) Revenue by Region: 2021-2032
- 5.3.1 Global Human Rabies Immune Globulin (HRIG) Revenue by Region: 2021-2026
- 5.3.2 Global Human Rabies Immune Globulin (HRIG) Revenue by Region: 2027-2032
- 5.4 North America Human Rabies Immune Globulin (HRIG) Market Facts & Figures by Country
- 5.4.1 North America Human Rabies Immune Globulin (HRIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Rabies Immune Globulin (HRIG) Sales by Country (2021-2032)
- 5.4.3 North America Human Rabies Immune Globulin (HRIG) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Human Rabies Immune Globulin (HRIG) Market Facts & Figures by Country
- 5.5.1 Europe Human Rabies Immune Globulin (HRIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Rabies Immune Globulin (HRIG) Sales by Country (2021-2032)
- 5.5.3 Europe Human Rabies Immune Globulin (HRIG) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Human Rabies Immune Globulin (HRIG) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Rabies Immune Globulin (HRIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Rabies Immune Globulin (HRIG) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Rabies Immune Globulin (HRIG) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Rabies Immune Globulin (HRIG) Market Facts & Figures by Country
- 5.7.1 South America Human Rabies Immune Globulin (HRIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Rabies Immune Globulin (HRIG) Sales by Country (2021-2032)
- 5.7.3 South America Human Rabies Immune Globulin (HRIG) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Human Rabies Immune Globulin (HRIG) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Rabies Immune Globulin (HRIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Rabies Immune Globulin (HRIG) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Rabies Immune Globulin (HRIG) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Human Rabies Immune Globulin (HRIG) Sales by Type (2021-2032)
- 6.1.1 Global Human Rabies Immune Globulin (HRIG) Sales by Type (2021-2032) & (K Tons)
- 6.1.2 Global Human Rabies Immune Globulin (HRIG) Sales Market Share by Type (2021-2032)
- 6.2 Global Human Rabies Immune Globulin (HRIG) Revenue by Type (2021-2032)
- 6.2.1 Global Human Rabies Immune Globulin (HRIG) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Rabies Immune Globulin (HRIG) Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Rabies Immune Globulin (HRIG) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Rabies Immune Globulin (HRIG) Sales by Application (2021-2032)
- 7.1.1 Global Human Rabies Immune Globulin (HRIG) Sales by Application (2021-2032) & (K Tons)
- 7.1.2 Global Human Rabies Immune Globulin (HRIG) Sales Market Share by Application (2021-2032)
- 7.2 Global Human Rabies Immune Globulin (HRIG) Revenue by Application (2021-2032)
- 7.2.1 Global Human Rabies Immune Globulin (HRIG) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Rabies Immune Globulin (HRIG) Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Rabies Immune Globulin (HRIG) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Rabies Immune Globulin (HRIG) Value Chain Analysis
- 8.1.1 Human Rabies Immune Globulin (HRIG) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Rabies Immune Globulin (HRIG) Production Mode & Process
- 8.2 Human Rabies Immune Globulin (HRIG) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Rabies Immune Globulin (HRIG) Distributors
- 8.2.3 Human Rabies Immune Globulin (HRIG) Customers
9 Global Human Rabies Immune Globulin (HRIG) Analyzing Market Dynamics
- 9.1 Human Rabies Immune Globulin (HRIG) Industry Trends
- 9.2 Human Rabies Immune Globulin (HRIG) Industry Drivers
- 9.3 Human Rabies Immune Globulin (HRIG) Industry Opportunities and Challenges
- 9.4 Human Rabies Immune Globulin (HRIG) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst